These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 3708874)

  • 1. Depot-bromocriptine treatment for prolactinomas and acromegaly.
    Grossman A; Ross R; Wass JA; Besser GM
    Clin Endocrinol (Oxf); 1986 Feb; 24(2):231-8. PubMed ID: 3708874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of a long-acting injectable form of bromocriptine in patients with prolactin and growth hormone secreting macroadenomas.
    Tsagarakis S; Tsiganou E; Tzavara I; Nikolou H; Thalassinos N
    Clin Endocrinol (Oxf); 1995 Jun; 42(6):593-9. PubMed ID: 7634499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parenteral bromocriptine in the treatment of hormonally active pituitary tumours.
    Benker G; Gieshoff B; Freundlieb O; Windeck R; Schulte HM; Lancranjan I; Reinwein D
    Clin Endocrinol (Oxf); 1986 May; 24(5):505-13. PubMed ID: 3791649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a repeatable depot-bromocriptine preparation(Parlodel LAR) for the treatment of acromegaly.
    Plöckinger U; Quabbe HJ
    J Endocrinol Invest; 1991 Dec; 14(11):943-8. PubMed ID: 1806612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of prolactin in the inhibitory action of bromocriptine on growth hormone secretion in acromegaly.
    Lamberts SW; Klijn JG; van Vroonhoven CC; Stefanko SZ; Liuzzi A
    Acta Endocrinol (Copenh); 1983 Aug; 103(4):446-50. PubMed ID: 6310918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term treatment of acromegalic patients with repeatable parenteral depot-bromocriptine.
    Jaspers C; Haase R; Pfingsten H; Benker G; Reinwein D
    Clin Investig; 1993 Jul; 71(7):547-51. PubMed ID: 8374248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of pituitary-tumour size in patients with prolactinomas and acromegaly treated with bromocriptine with or without radiotherapy.
    Wass JA; Moult PJ; Thorner MO; Dacie JE; Charlesworth M; Jones AE; Besser GM
    Lancet; 1979 Jul; 2(8133):66-9. PubMed ID: 87966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-lasting suppression of prolactin secretion and rapid shrinkage of prolactinomas after a long-acting, injectable form of bromocriptine.
    Montini M; Pagani G; Gianola D; Pagani MD; Salmoiraghi M; Ferrari L; Lancranjan I
    J Clin Endocrinol Metab; 1986 Jul; 63(1):266-8. PubMed ID: 3711262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA synthesis by pituitary tumours, with reference to plasma hormone levels and to effects of bromocriptine.
    Lloyd HM; Jacobi JM; Willgoss DA
    Clin Endocrinol (Oxf); 1995 Jul; 43(1):79-85. PubMed ID: 7641414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis and drug therapy of prolactinoma.
    Ciccarelli E; Camanni F
    Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bromocriptine, a dopamine agonist, increases growth hormone secretion in a patient with acromegaly.
    Arihara Z; Sakurai K; Yamashita R; Niitsuma S; Ueno T; Yamamura N; Yamada S; Inoshita N; Takahashi K
    Tohoku J Exp Med; 2014 Oct; 234(2):129-35. PubMed ID: 25253414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Control of prolactin-secreting macroadenomas with parenteral, long-acting bromocriptine in 30 patients treated for up to 3 years.
    Haase R; Jaspers C; Schulte HM; Lancranja I; Pfingsten H; Orri-Fend M; Reinwein D; Benker G
    Clin Endocrinol (Oxf); 1993 Feb; 38(2):165-76. PubMed ID: 8435897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the new dopaminergic agonist CV 205-502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas.
    Duranteau L; Chanson P; Lavoinne A; Horlait S; Lubetzki J; Kuhn JM
    Clin Endocrinol (Oxf); 1991 Jan; 34(1):25-9. PubMed ID: 1672268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to bromocriptine in prolactinomas.
    Pellegrini I; Rasolonjanahary R; Gunz G; Bertrand P; Delivet S; Jedynak CP; Kordon C; Peillon F; Jaquet P; Enjalbert A
    J Clin Endocrinol Metab; 1989 Sep; 69(3):500-9. PubMed ID: 2760167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bromocriptine treatment over 12 years in acromegaly: effect on growth hormone and prolactin secretion.
    Rau H; Althoff PH; Schmidt K; Usadel KH
    Acta Endocrinol (Copenh); 1992 Mar; 126(3):247-52. PubMed ID: 1574954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with octreotide and bromocriptine in patients with acromegaly: an open pharmacodynamic interaction study.
    Fredstorp L; Kutz K; Werner S
    Clin Endocrinol (Oxf); 1994 Jul; 41(1):103-8. PubMed ID: 8050122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolactin secretion in the empty sella syndrome, in prolactinomas and in acromegaly.
    Brismar K
    Acta Med Scand; 1981; 209(5):397-405. PubMed ID: 6787839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The rapid diagnosis of sensitivity or resistance to dopamine agonists with depot bromocriptine.
    Grossman A; Wass JA; Besser M
    Acta Endocrinol (Copenh); 1987 Oct; 116(2):275-81. PubMed ID: 3661064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in plasma GH levels and clinical activity during bromocriptine therapy in acromegaly. The value of predictive tests.
    Nortier JW; Croughs RJ; Donker GH; Thijssen JH; Schwarz F
    Acta Endocrinol (Copenh); 1984 Jun; 106(2):175-83. PubMed ID: 6145276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bromocriptine treatment of prolactin-secreting pituitary adenomas may restore pituitary function.
    Warfield A; Finkel DM; Schatz NJ; Savino PJ; Snyder PJ
    Ann Intern Med; 1984 Dec; 101(6):783-5. PubMed ID: 6497193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.